Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19
Introduction The study aim was to assess the influence of inflammatory response modifiers, including anti-interleukin-6 (IL-6) biologics and corticosteroids, on the incidence of hospital-acquired infections in patients with coronavirus disease 2019 (COVID-19). Methods Case–control study performed at a university hospital from February 26 to May 26, 2020. Cases were defined as patients with COVID-19 who developed hospital-acquired infections. For each case, two controls were selected among patients without infections. Cases and controls were matched obeying three criteria in a hierarchical sequence: length of hospital stay up until the first infection; comorbidity; and need for Intensive care unit (ICU) admission. Conditional logistic regression analysis was used to estimate the association of exposures with being a case. Results A total of 71 cases and 142 controls were included. Independent predictors for acquiring a hospital infection were chronic liver disease [odds ratio (OR) 16.56, 95% CI 1.87–146.5, p = 0.012], morbid obesity (OR 6.11, 95% CI 1.06–35.4, p = 0.043), current or past smoking (OR 4.15, 95% CI 1.45–11.88, p = 0.008), exposure to hydroxychloroquine (OR 0.2, 95% CI 0.041–1, p = 0.053), and invasive mechanical ventilation (OR 61.5, 95% CI 11.08–341, p ≤ 0.0001). Conclusions Inflammatory response modifiers had no influence on acquisition of nosocomial infections in admitted patients with COVID-19. Hospital-acquired infections primarily occurred in the critically ill and invasive mechanical ventilation was the main exposure conferring risk..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 10(2021), 3 vom: 11. Juni, Seite 1407-1418 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meira, Fernanda [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1007/s40121-021-00477-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR04469962X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR04469962X | ||
| 003 | DE-627 | ||
| 005 | 20230519231600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210730s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-021-00477-9 |2 doi | |
| 035 | |a (DE-627)SPR04469962X | ||
| 035 | |a (SPR)s40121-021-00477-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Meira, Fernanda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Introduction The study aim was to assess the influence of inflammatory response modifiers, including anti-interleukin-6 (IL-6) biologics and corticosteroids, on the incidence of hospital-acquired infections in patients with coronavirus disease 2019 (COVID-19). Methods Case–control study performed at a university hospital from February 26 to May 26, 2020. Cases were defined as patients with COVID-19 who developed hospital-acquired infections. For each case, two controls were selected among patients without infections. Cases and controls were matched obeying three criteria in a hierarchical sequence: length of hospital stay up until the first infection; comorbidity; and need for Intensive care unit (ICU) admission. Conditional logistic regression analysis was used to estimate the association of exposures with being a case. Results A total of 71 cases and 142 controls were included. Independent predictors for acquiring a hospital infection were chronic liver disease [odds ratio (OR) 16.56, 95% CI 1.87–146.5, p = 0.012], morbid obesity (OR 6.11, 95% CI 1.06–35.4, p = 0.043), current or past smoking (OR 4.15, 95% CI 1.45–11.88, p = 0.008), exposure to hydroxychloroquine (OR 0.2, 95% CI 0.041–1, p = 0.053), and invasive mechanical ventilation (OR 61.5, 95% CI 11.08–341, p ≤ 0.0001). Conclusions Inflammatory response modifiers had no influence on acquisition of nosocomial infections in admitted patients with COVID-19. Hospital-acquired infections primarily occurred in the critically ill and invasive mechanical ventilation was the main exposure conferring risk. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammatory response modifiers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nosocomial infections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Moreno-García, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Linares, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Macaya, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Tomé, Adria |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Meneses, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Albiach, Laia |e verfasserin |4 aut | |
| 700 | 1 | |a Morata, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Letona, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bodro, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Cózar-Llistó, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Cardozo, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Chumbita, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Pitart, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrosioni, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Rico, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Agüero, Daiana |e verfasserin |4 aut | |
| 700 | 1 | |a Puerta-Alcalde, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Pouton, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Marco, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Vidal, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, José Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d Heidelberg : Springer, 2012 |g 10(2021), 3 vom: 11. Juni, Seite 1407-1418 |w (DE-627)SPR032878133 |w (DE-600)2701611-0 |x 2193-6382 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:3 |g day:11 |g month:06 |g pages:1407-1418 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40121-021-00477-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 3 |b 11 |c 06 |h 1407-1418 | ||